NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Buy ATXI with Qtrade Free ATXI Stock Alerts $6.20 +6.08 (+5,066.67%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$5.78▼$8.8350-Day Range$7.07▼$14.4052-Week Range$5.78▼$93.75Volume234,022 shsAverage Volume63,669 shsMarket Capitalization$274.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaSustainability Get Avenue Therapeutics alerts: Email Address Avenue Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.44% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment-0.23Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.86 out of 5 starsMedical Sector805th out of 913 stocksPharmaceutical Preparations Industry374th out of 420 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avenue Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the outstanding shares of Avenue Therapeutics have been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently decreased by 31.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvenue Therapeutics has received a 73.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Avenue Therapeutics is -0.99. Previous Next 1.5 News and Social Media Coverage News SentimentAvenue Therapeutics has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Avenue Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 5 people have searched for ATXI on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows3 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 206.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesApril 27, 2024 | msn.comLarge police presence briefly shuts down Forest Avenue in PortlandApril 26, 2024 | msn.comOne wounded in Lakeside Avenue shooting near ColumbiaApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 26, 2024 | msn.comPro-Palestine rally blocks one side of St. Charles AvenueApril 26, 2024 | msn.comRocky Hill crash shuts down New Britain AvenueApril 26, 2024 | investing.comAvenue Therapeutics Inc (ATXI)April 26, 2024 | yahoo.comCrash on Dale Avenue SE causes delays in RoanokeApril 26, 2024 | msn.comEvansville Homeowner Loses Everything in Denby Avenue FireApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 26, 2024 | msn.comVietnamese restaurant opens on Central Avenue, beside Landmark Diner and Manolo’s BakeryApril 26, 2024 | msn.comTraffic collision reported on Pershing Avenue in StocktonApril 26, 2024 | msn.comWhy are there construction crews along Millwood Avenue in Columbia?April 24, 2024 | msn.comWhy Avenue Therapeutics (ATXI) Shares Are Getting HammeredApril 24, 2024 | globenewswire.comAvenue Therapeutics Announces Reverse Stock SplitApril 17, 2024 | americanbankingnews.comAvenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 9.7% in MarchApril 5, 2024 | msn.comSaks Fifth Avenue set to close at Fashion Mall at KeystoneApril 5, 2024 | msn.com2 suspects identified in connection with Euclid Avenue shooting: Mobile PoliceApril 5, 2024 | msn.comNew updates on revitalizations of Nashville’s 2nd Avenue years after Christmas Day bombingApril 5, 2024 | msn.comBurbank Man Found Deceased In Bus Shelter On Harlem AvenueApril 5, 2024 | msn.comDowntown Minneapolis' First Avenue N. corridor to get $30 million facelift, first big upgrade in decadesApril 5, 2024 | yahoo.comFatal crash shuts down I-43 southbound at Hampton Avenue for hoursApril 4, 2024 | msn.comTasing reported on Washington Avenue in North AvondaleApril 4, 2024 | msn.comHouse containing adults and child damaged by gunfire on Lyell AvenueApril 4, 2024 | msn.comPolice investigating school bus crash on Colerain Avenue in Mount AiryApril 3, 2024 | msn.comRoc Paint Division brings Boston artist for 'caring' mural at Avenue D R-CenterApril 3, 2024 | msn.comShooting reported on Glenwood Avenue in AvondaleApril 3, 2024 | msn.comWires reported down on Pennsylvania Avenue in York CitySee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/27/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-335.11% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book206.67Miscellaneous Outstanding Shares44,260,000Free Float43,464,000Market Cap$274.41 million OptionableNot Optionable Beta-0.24 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 56)CEO & Director Comp: $413.2kMr. David Jin (Age 33)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Xiaoqin Lu M.D. (Age 49)Consultant Comp: $1.05MDr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kMr. Srinivas Subramanian (Age 53)Executive Vice President More ExecutivesKey CompetitorsXenetic BiosciencesNASDAQ:XBIOHoth TherapeuticsNASDAQ:HOTHAyala PharmaceuticalsNASDAQ:ADXSVaccinexNASDAQ:VCNXAinosNASDAQ:AIMDView All CompetitorsInsidersFortress Biotech, Inc.Bought 5,578 shares on 9/8/2023Total: $301,212.00 ($54.00/share)Lindsay A Md RosenwaldBought 4,649 shares on 9/8/2023Total: $251,046.00 ($54.00/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. How have ATXI shares performed in 2024? Avenue Therapeutics' stock was trading at $12.0750 at the start of the year. Since then, ATXI shares have decreased by 48.7% and is now trading at $6.20. View the best growth stocks for 2024 here. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 283,100 shares, a decline of 9.7% from the March 15th total of 313,400 shares. Based on an average trading volume of 2,290,000 shares, the short-interest ratio is presently 0.1 days. View Avenue Therapeutics' Short Interest. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) released its quarterly earnings data on Monday, March, 18th. The company reported $42.00 earnings per share for the quarter. When did Avenue Therapeutics' stock split? Avenue Therapeutics's stock reverse split before market open on Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
